Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023